Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria

J Cutan Med Surg. 2020 Mar/Apr;24(2):201-202. doi: 10.1177/1203475419888873.

Authors

Anastasiya Muntyanu¹, Lydia Ouchene¹, Moshe Ben-Shoshan², Elena Netchiporouk¹

Affiliations

¹ 54473 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.
² 12367 Division of Allergy Clinical Immunology and Dermatology, Department of Pediatrics, Montreal Children's Hospital, McGill University, QC, Canada.

PMID: 32208012
DOI: 10.1177/1203475419888873

No abstract available

Keywords: chronic spontaneous urticaria; chronic urticaria; ligelizumab; omalizumab.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Chronic Urticaria*
Humans
Omalizumab
Urticaria*

Substances

Antibodies, Monoclonal, Humanized
Omalizumab
ligelizumab